Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melinda Auer

Gynecology Chesterfield, MO Medical Doctor

NPI 1326336314 CMS profile 1351741

16216 Baxter Rd Ste 100, Chesterfield, MO 63017

Open in the dashboard

General payments

$1,841

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melinda Auer of Chesterfield, MO is reported in the CMS Open Payments database as having received $1,841 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 13
2024 General $178 10
2023 General $118 8
2022 General $436 27
2021 General $566 33
2020 General $48 3
2019 General $207 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melinda Auer
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Melinda Auer were reported at $288. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Melinda Auer Gynecology median Middle half National median
2019 $207 $199 $66–$472 $163
2020 $48 $114 $42–$287 $114
2021 $566 $141 $42–$430 $132
2022 $436 $173 $52–$532 $149
2023 $118 $170 $57–$501 $160
2024 $178 $157 $50–$424 $164
2025 $288 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $887 49 payments
  2. Allergan Inc. $185 11 payments
  3. Mayne Pharma Inc. $166 8 payments
  4. Organon LLC $122 9 payments
  5. Merck Sharp & Dohme Corporation $98 8 payments
  6. Amgen Inc. $56 3 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $44 3 payments
  8. Sumitomo Pharma America, Inc. $42 2 payments
  9. Pfizer Inc. $32 2 payments
  10. TherapeuticsMD, Inc. $23 2 payments
  11. Other $185 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,834 107 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $605 29 payments
  2. LO LOESTRIN FE $339 23 payments
  3. NEXPLANON Etonogestrel $122 9 payments
  4. NEXPLANON Womens Health $98 8 payments
  5. GARDASIL9 $57 5 payments
  6. EVENITY $56 3 payments
  7. Prolia $56 3 payments
  8. TAYTULLA $51 3 payments
  9. ORIAHNN $38 3 payments
  10. UBRELVY Neuroscience $35 2 payments
  11. Other $600 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$2,558

Medicare's payments for the services billed

Medicare patients

20

Average age 71

Services billed

32

20 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 55%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $35
$35 — —
PAXLOVID
  • PFIZER INC. $25
$25 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $24
$24 — —
NURTEC ODT
  • PFIZER INC. $7
$7 — —
Mirena
  • Bayer HealthCare Pharmaceuticals Inc. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record